MoonLake Immunotherapeutics
MoonLake Immunotherapeutics (MLTX): 3 pipeline candidates · 5 upcoming catalysts · ~17 mo cash runway · 10 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
16.6 months
D/E 0.58
Lead: Phase 3
3 candidates
5 upcoming, next in ~102d
0 buys · 9 sells (180d)
A transparent, data-derived signal for MoonLake Immunotherapeuticsacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$1.4B
Cash
$298.5M
Quarterly Burn
$66.3M
Runway
16.6 mo
Revenue
—
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (3 candidates)
| Drug | Phase |
|---|---|
| Risankizumab | Phase 3 |
| SLK | Phase 2 |
| Sonelokimab | Phase 1 |
Upcoming Catalysts (5)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
145
Total value held
$1.13B
| Holder | Shares | Value |
|---|---|---|
| bvf inc/il | 16,001,284 | $298.3M |
| janus henderson group plc | 6,903,256 | $128.6M |
| deep track capital, lp | 6,408,863 | $119.5M |
| d. e. shaw & co., inc. | 2,390,661 | $44.6M |
| citadel advisors llc | 2,081,728 | $38.8M |
| vivo capital, llc | 2,000,000 | $37.3M |
| mpm bioimpact llc | 1,811,082 | $33.8M |
| weiss asset management lp | 1,708,328 | $31.8M |
| susquehanna international group, llp | 1,208,624 | $22.5M |
| goldman sachs group inc | 1,130,233 | $21.1M |
Showing top 10 of 145 institutional holders of MoonLake Immunotherapeutics. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in MoonLake Immunotherapeutics's pipeline?
MoonLake Immunotherapeutics (MLTX) has 3 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is MoonLake Immunotherapeutics's lead drug candidate?
MoonLake Immunotherapeutics's most advanced tracked candidate is Risankizumab (Phase 3) for Arthritis, Psoriatic.
What is MoonLake Immunotherapeutics's next catalyst?
MoonLake Immunotherapeutics's next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: An Open-label, Single-arm Study to Evaluate the Pharmacokinetics and Safety of Subcutaneous Soneloki" — expected September 28, 2026.
What is MoonLake Immunotherapeutics's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, MoonLake Immunotherapeutics has approximately 16.6 months of cash runway.
What is MoonLake Immunotherapeutics's market capitalization?
MoonLake Immunotherapeutics's market capitalization is approximately $1.4B.
Get the full picture on MoonLake Immunotherapeutics
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.